Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.44 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | JAK1 | P23458 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | TACR1 | P25103 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | STS | P08842 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31450056 | 0.91 | TSHR (0.45) | GPR119JAK2JAK1KDM4EPKM | |
| SCHEMBL1105801 | 0.91 | BRD4 (0.49) | GPR119JAK2JAK1KDM4EPKM | |
| SCHEMBL1105715 | 0.91 | BRD4 (0.49) | GPR119JAK2JAK1KDM4EPKM | |
| SCHEMBL5006580 | 0.89 | GPR119 (0.44) | GPR119JAK2JAK1KDM4EPKM | |
| SCHEMBL5006571 | 0.89 | GPR119 (0.44) | GPR119JAK2JAK1KDM4EPKM | |
| SCHEMBL4004318 | 0.88 | PKM (0.51) | GPR119JAK2JAK1KDM4EPKM | |
| SCHEMBL3010603 | 0.88 | PKM (0.51) | GPR119JAK2JAK1KDM4EPKM | |
| SCHEMBL3004868 | 0.88 | PKM (0.51) | GPR119JAK2JAK1KDM4EPKM | |
| SCHEMBL7904145 | 0.88 | PKM (0.51) | GPR119JAK2JAK1KDM4EPKM | |
| SCHEMBL1105755 | 0.88 | PKM (0.51) | GPR119JAK2JAK1KDM4EPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008133344-A2 | PIPERIDINE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-11-06 | — | — | WO | disclosed |
| US-20080275085-A1 | Piperidine derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275085-A1 | Piperidine derivative and use thereof | TACR2, TACR1, PRLHR | GPR119 105/4885JAK2 205/4885JAK1 1048/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.